Securing a groundbreaking regulatory approval for the first PROTAC, VEPPANU, has been a major achievement. It marks a significant milestone in the field of heterobifunctional protein degraders. Following the approval, the successful out-licensing to Rigel Pharmaceuticals has been completed. This development showcases the potential of PROTACs in the pharmaceutical industry. This is indeed a momentous accomplishment in the progress of targeted protein degradation.